Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results
October 8, 2015 2:49 PM EDTLeerink Partners reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX), and raised the price target to $71.00 (from $67.00), following positive KINECT3 results. Analyst Paul Matteis We sees the likelihood of the emergence of an unexpected long-term safety signal as very low, but still possible given the patient population under surveillance.
Matteis commented, "On the heels of positive... More
Neurocrine Bio (NBIX) PT Raised to $96 at Piper Jaffray
October 8, 2015 10:52 AM EDTPiper Jaffray analyst Charles C. Duncan reiterated an Overweight rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $86.00).
Duncan commented, "Today Neurocrine announced positive Phase III results on '854 in Tardive Dyskinesia patients with an underlying psychiatric disorder. Although... More
Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive Dyskinesia
October 8, 2015 6:34 AM EDTNeurocrine Biosciences (NASDAQ: NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying... More
